September 30, 2021 11:39 ET | Source: Center for Innovative Technology

Richmond, VA, 30 September 2021, (GLOBE NEWSWIRE) — King George, VA-based Impruvon Virginia with offices in Manassas, Virginia, has received investment from CIT GAP Funds, the direct investment programme of the Virginia Innovation Partnership Authority (VIPA) Investment Division, according to a recent announcement from the Center for Innovative Technology (CIT). Impruvon is a platform created to simplify, protect, automate and revolutionize medication management for both staff and residents in long-term care facilities.

More than 100,000 reports of suspected medication errors are sent to the U.S. Food and Drug Administration (FDA) each year. Theft or misuse of pharmaceutical doses and a general lack of medication compliance, such as missing doses, are typical issues. Impruvon Health enhances the lives of those who care for people & those with difficult-to-maintain prescription regimens, whether they live at home or in long-term care facilities. The Impruvon Health Platform automates the storage, administration, and record-keeping of medications by doing away with manual labour while promoting independence and security for the patient being treated.

“Having experienced the detrimental impacts that medication errors can have on individuals and their families first hand, our team has a unique understanding of our customers. At Impruvon, we understand the importance of having one easily accessible place for all your medication data, and have the tools to make that experience possible,” according to Justin Amoyal, CEO and Co-Founder of Impruvon.“We look forward to expanding our brand and getting our technology platform out there to a wider user base. We are thrilled to have the support of CIT GAP Funds and look forward to our next phase of growth.”

We target neuro-diverse individuals, those undergoing recovery from addiction, and veterans – & assure data is protected and accessible in real time.

“Healthcare is an industry where accuracy is extremely important, and there are far too many instances of inaccuracy and mismanagement. Impruvon has a motivated and talented team building a platform that ensures smart medication management for long term care, and has a great opportunity to address this issue in the medical industry,” Tom Weithman, Managing Director, CIT GAP Funds added. “The team has already conducted over 500 customer discovery interviews informing their product. Having a distinctly unique understanding of their customers has led to the team signing multiple pilot testing agreements. CIT looks forward to following Impruvon as they continue to grow and make a positive impact on the lives of both patients and caregivers.”